早期应用阿托伐他汀对急性冠脉综合征患者远期疗效的影响

目的观察阿托伐他汀对急性冠状动脉综合征（ACS）患者早期炎症因子和心脑血管事件的干预效果。方法将53例ACS患者随机分为阿托伐他汀治疗组（n=29）和常规对照组（n=24）。阿托伐他汀治疗组在对照组常规治疗基础上加用阿托伐他汀20mg,每晚1次顿服。所有患者分别于入院24h内和治疗后1个月清晨空腹采血1次,测定血脂、hs-CRP、MMP-9。同时观察6个月随访期内主要心脑血管终点事件的发生。结果治疗4周后,阿托伐他汀治疗组与对照组相比,患者TC、TG、hs-CRP及MMP-9浓度显著降低（均P〈0.01）,而对照组治疗前后差异无统计学意义（P〉0.05）。阿托伐他汀治疗组6个月随访期内复发性心绞痛、心律失常、心力衰竭及非致命性心肌梗塞等均较常规对照组明显降低（P〈0.05）。结论阿托伐他汀早期治疗ACS能够抑制炎症因子并降低半年随访期间主要心血管事件的发生率。

Early Application of Atorvastatin on Long-term Efficacy in Patients with Acute Crownary Syndrome

Objective To observe intervention effect of atorvastatin in patients with acute coronary syndrome of early inflammatory factors and cardiovascular and cerebrovascular events.Methods Totally 53 patients with ACS were randomly assigned to atorvastatin treatment group （n=29） and conventional control group （n=24）.Atorvastatin treatment group based on the control group conventional therapy plus atorvastatin 20mg,per night 1 service.all patients at 24h and admitted to hospital and treatment 1 month later the fasting blood one time to measure lipids,hs-CRP,MMP-9.While observing the 6 month follow-up,the main cardio-cerebral vascular events.Results After 4 weeks of atorvastatin treatment group compared with the control group,patients with TC,TG,hs-CRP and MMP-9 levels were significantly decreased （both P0.01）,while the control group,no statistical difference before and after therapy （P0.05）.Atorvastatin treatment group,6-month follow-up period recurrent angina,arrhythmia,heart failure and non-fatal myocardial infarction was significantly lower than those in normal controls （P0.05）.Conclusion Early treatment of ACS atorvastatin can inhibit inflammatory cytokines and reduce follow-up period of six months,the incidence of major cardiovascular events.